Septerna Inc (SEPN) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases.
Is Septerna Inc stock overvalued or undervalued in 2026?
As of November 3, 2026, Septerna Inc (SEPN) trades at $43.70 with no positive earnings over the last twelve months, according to Kaplio. No valuation verdict: it has no earnings to calculate a P/E from.
Kaplio overview: Septerna Inc
Market cap $2B · 52 weeks $18 – $48 (10 % below the high) · P/E no earnings · Dividend none · Next earnings November 9, 2026 · expected EPS -$0.41 · Closing price, Nov 3 · accounts published Aug 10.
- Valuation: P/Sales 37.1× (no earnings).
- Balance sheet: Safe zone (solid).
- Earnings: 3 of 8 (disappointing).
What would it be worth at its usual multiples?
No valuation verdict: it has no earnings to calculate a P/E from.
What matters in biotech: 2 of 4 pass
- R&D / Market cap 5.0 %, fails.
- Market cap / Cash 4.9×, fails.
- Annual cash burn $2.49, passes.
- Total Debt 0.1×, passes.
Against its peers (reference peers) — Septerna Inc: P/E —; EV/EBITDA —; ROIC -8.9 %; $2.0B. Vericel Corporation (P/E 87.8×; EV/EBITDA 52.6×; ROIC 3.8 %; $2.1B), Lakefront Biotherapeutics N.V. (P/E 3.9×; EV/EBITDA 5.2×; ROIC 11.6 %; $2.1B), Harmony Biosciences Holdings, Inc. (P/E 12.0×; EV/EBITDA 6.7×; ROIC 15.0 %; $2.2B).
Profitability
| Return on Equity | -6.31% |
| Return on Invested Capital | -8.89% |
| Return on Assets | -4.28% |
| Gross Margin | 99.57% |
| Operating Margin | -44.04% |
| Net Margin | -24.51% |
Financial Health
| Debt / Equity | 0.06 |
| Current Ratio | 4.99 |
| Piotroski F-Score | 4 |
| Altman Z-Score | 3.34 |
Price Performance
| 1 month | +14.07% |
| 3 months | +9.28% |
| Year-to-date | +54.95% |
| 1 year | +121.99% |
Related companies: MBX · VRTX · 0QZU.L · REGN · MRNA · 0R2M.L · ARGX · 0QNO.L
Explore sector: Healthcare · Biotechnology
More sections of SEPN: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks